Hepatic resection (HR) and radiofrequency ablation (RFA) are popular local therapies for early-stage hepatocellular carcinoma (HCC).Alpha-fetoprotein,Lens culinaris agglutininreactive fraction of alpha-fetoprotein,and...Hepatic resection (HR) and radiofrequency ablation (RFA) are popular local therapies for early-stage hepatocellular carcinoma (HCC).Alpha-fetoprotein,Lens culinaris agglutininreactive fraction of alpha-fetoprotein,and des-c-carboxy prothrombin are well-known and useful tumor markers for HCC.The positive number status of these tumor markers has recently been demonstrated as beneficial for predicting outcome for HCC patients treated with local therapy.Although the normal ranges reported have differed by institution,the positivity of tumor markers is consistent and can easily be assessed.Kumamoto and Wakayama's group clearly demonstrated the following:1) Regardless of the degree of tumor stage,a triple-positive tumor marker profile can predict poor outcome in HCC patients undergoing HR;2) For RFA alone,HCC patients with double-and triple-positive status,having less than three lesions and lesions ≤3 cm in diameter show comparably insufficient outcomes;3) For HCC patients with lesions ≤5 cm in Child-Pugh grade A,HR is preferred over RFA;4) Microvascular invasion rates increased even in the double-positive patients,while poorly differentiated HCC was frequently observed only in the triple-positive patients;and 5) RFA with chemoembolization,anatomical liver resection,and postoperative adjuvant chemoembolization or hepatic arterial chemotherapy might improve the outcome for patients with highly malignant HCC with multiple positive tumor markers.However,the impacts of these therapies still need to be evaluated in prospective comparative studies.展开更多
三阳性乳腺癌(triple-positive breast cancer,TPBC)是乳腺癌分子分型中特殊的一类,以ER/PR/HER-2均阳性表达为特征,对化疗、靶向治疗、内分泌治疗都具有敏感性。虽然理论上联合治疗可能使患者获得更好的治疗效果,但是TPBC的治疗没有得...三阳性乳腺癌(triple-positive breast cancer,TPBC)是乳腺癌分子分型中特殊的一类,以ER/PR/HER-2均阳性表达为特征,对化疗、靶向治疗、内分泌治疗都具有敏感性。虽然理论上联合治疗可能使患者获得更好的治疗效果,但是TPBC的治疗没有得到期望的预后。因此探索其临床特征、耐药机制及针对性治疗是今后的发展方向。展开更多
目的:探讨三阳性乳腺癌(triple-positive breast cancer,TPBC)患者的临床病理特征及预后。方法:收集2010年9月至2015年9月我院收治的TPBC患者130例,对其临床病理资料进行回顾性分析。结果:研究中,TPBC患者共130例,占所有乳腺癌患者的13....目的:探讨三阳性乳腺癌(triple-positive breast cancer,TPBC)患者的临床病理特征及预后。方法:收集2010年9月至2015年9月我院收治的TPBC患者130例,对其临床病理资料进行回顾性分析。结果:研究中,TPBC患者共130例,占所有乳腺癌患者的13.10%。其中,63.08%为超重/肥胖患者(BMI≥24),52.31%的患者合并有慢性病。患者最常见的首诊症状为发现乳房肿块(80例,占61.54%),而非疼痛(10例,占7.69%)。病灶的位置以右侧多见(75例,占57.69%),最常见的部位为外上象限(58例,占44.62%)。最常见病理学类型为浸润性导管癌(104例,占80.00%)。随访结果表明,局部复发率为9.23%(12例),远处转移率为26.92%(35例)。最常见的转移部位为骨(24例,占68.57%),其次为肺(18例,占51.43%)。结论:TPBC患者的预后较差,容易发生远处转移,且有早期转移倾向,因此迫切需要对TPBC进行全面的研究,更深入的了解TPBC的异质性。展开更多
文摘Hepatic resection (HR) and radiofrequency ablation (RFA) are popular local therapies for early-stage hepatocellular carcinoma (HCC).Alpha-fetoprotein,Lens culinaris agglutininreactive fraction of alpha-fetoprotein,and des-c-carboxy prothrombin are well-known and useful tumor markers for HCC.The positive number status of these tumor markers has recently been demonstrated as beneficial for predicting outcome for HCC patients treated with local therapy.Although the normal ranges reported have differed by institution,the positivity of tumor markers is consistent and can easily be assessed.Kumamoto and Wakayama's group clearly demonstrated the following:1) Regardless of the degree of tumor stage,a triple-positive tumor marker profile can predict poor outcome in HCC patients undergoing HR;2) For RFA alone,HCC patients with double-and triple-positive status,having less than three lesions and lesions ≤3 cm in diameter show comparably insufficient outcomes;3) For HCC patients with lesions ≤5 cm in Child-Pugh grade A,HR is preferred over RFA;4) Microvascular invasion rates increased even in the double-positive patients,while poorly differentiated HCC was frequently observed only in the triple-positive patients;and 5) RFA with chemoembolization,anatomical liver resection,and postoperative adjuvant chemoembolization or hepatic arterial chemotherapy might improve the outcome for patients with highly malignant HCC with multiple positive tumor markers.However,the impacts of these therapies still need to be evaluated in prospective comparative studies.
文摘三阳性乳腺癌(triple-positive breast cancer,TPBC)是乳腺癌分子分型中特殊的一类,以ER/PR/HER-2均阳性表达为特征,对化疗、靶向治疗、内分泌治疗都具有敏感性。虽然理论上联合治疗可能使患者获得更好的治疗效果,但是TPBC的治疗没有得到期望的预后。因此探索其临床特征、耐药机制及针对性治疗是今后的发展方向。
文摘目的:探讨三阳性乳腺癌(triple-positive breast cancer,TPBC)患者的临床病理特征及预后。方法:收集2010年9月至2015年9月我院收治的TPBC患者130例,对其临床病理资料进行回顾性分析。结果:研究中,TPBC患者共130例,占所有乳腺癌患者的13.10%。其中,63.08%为超重/肥胖患者(BMI≥24),52.31%的患者合并有慢性病。患者最常见的首诊症状为发现乳房肿块(80例,占61.54%),而非疼痛(10例,占7.69%)。病灶的位置以右侧多见(75例,占57.69%),最常见的部位为外上象限(58例,占44.62%)。最常见病理学类型为浸润性导管癌(104例,占80.00%)。随访结果表明,局部复发率为9.23%(12例),远处转移率为26.92%(35例)。最常见的转移部位为骨(24例,占68.57%),其次为肺(18例,占51.43%)。结论:TPBC患者的预后较差,容易发生远处转移,且有早期转移倾向,因此迫切需要对TPBC进行全面的研究,更深入的了解TPBC的异质性。
